Article info

Original research
Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes

Authors

  1. Correspondence to Professor Derralynn A Hughes, Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London, London NW3 2QG, UK; derralynnhughes{at}nhs.net
View Full Text

Citation

Hughes DA, Bichet DG, Giugliani R, et al
Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes

Publication history

  • Received May 9, 2022
  • Accepted November 11, 2022
  • First published December 21, 2022.
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.